Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexadecyl Octanoate is a small molecule, specifically an ester, that has been identified as a fortuitous ligand for EthR, a repressor protein in Mycobacterium tuberculosis. Its binding to EthR induces a conformational change that renders the protein incompatible with its repressor function, leading to the derepression of the ethA gene. This mechanism suggests a therapeutic potential against tuberculosis by increasing the sensitivity of M. tuberculosis to existing antibiotics like ethionamide and other thioamides, thereby potentially allowing for reduced dosages of these toxic compounds. Beyond its biological activity, Hexadecyl Octanoate is also widely used as an emollient in cosmetic and personal care products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hexadecyl Octanoate.